Ultragenyx Pharmaceutical (RARE) Bank of America Global Healthcare Conference 2026 summary

Commercial performance and outlook

• Four commercialized products are expected to generate $730–$760 million in revenue this year, with CRYSVITA contributing $500–$520 million and showing single- to double-digit growth as growth levels off compared to previous years.

• Revenue guidance for the year was reaffirmed despite a slight quarterly miss, with expectations of a typical sawtooth pattern and some lumpiness in Latin America due to large contracts.

• Demand signals remain strong, and the company is on track for profitability by 2027, supported by growth in current programs and potential new launches.

• A cost savings program, including a 10% workforce reduction, is expected to reduce R&D and SG&A expenses, supporting the path to profitability.

• Priority review vouchers (PRVs) from new approvals are expected to provide additional financial flexibility.

Angelman syndrome program

• Phase III data for Angelman syndrome is expected in the second half of the year, with long-term phase I/II data showing sustained efficacy and no new safety concerns.

• The trial uses two primary endpoints: Bayley-4 cognition and MDRI, with alpha split between them to hedge risk and reflect clinical relevance.

• Patient populations in phase I/II and phase III are fully overlapping, supporting confidence in data translation.

• The addressable market is estimated at 60,000 patients globally, with a highly engaged patient community and a planned focused sales force for launch.

• The Aurora study will expand the eligible population, with enrollment expected to complete by year-end.

Gene therapy pipeline and launches

• Two gene therapy programs, DTX401 (GSDIa) and UX111 (Sanfilippo syndrome), have PDUFA dates in the second half of the year, with DTX401's date on August 23.

• DTX401 addresses a high unmet need, aiming to replace burdensome cornstarch regimens with a one-time therapy, targeting a $1–$2 million price point.

• UX111 targets a smaller population (3,000–5,000), with a potential price of $2–$4 million, and is positioned as a first-in-class therapy for a fatal disease.

• Both launches will leverage existing commercial infrastructure, with only minor expansion needed for specialized support.

• Manufacturing and inventory are prepared for both launches, with previously expensed inventory providing initial margin benefits.